首页> 外文期刊>International Journal of Pharmaceutics >Lipid-nucleic acid nanoparticles of novel ionizable lipids for systemic BMP-9 gene delivery to bone-marrow mesenchymal stem cells for osteoinduction
【24h】

Lipid-nucleic acid nanoparticles of novel ionizable lipids for systemic BMP-9 gene delivery to bone-marrow mesenchymal stem cells for osteoinduction

机译:新型可电离脂质的脂质 - 核酸纳米粒子用于全身性BMP-9基因递送至骨髓间充质干细胞的骨髓丁基

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Rational design of novel ionizable lipids for development of lipid-nucleic acid nanoparticles (LNP) is required for safe and effective systemic gene delivery for osteoporosis. LNPs require suitable characteristics for intravenous administration and effective accumulation in bone marrow for enhanced transfection. Hence, lipids with C18 tail and ionizable headgroup (Boc-His-ODA/BHODA and His-ODA/HODA) were synthesized and characterized physicochemically. LNPs were prepared with bone morphogenetic protein-9 gene (BHODA-LNP, HODA-LNP, and bone-homing peptide targeted HODA-LNP - HODA-LNPT). Thorough physicochemical (electrolyte stability, DNase I and serum stability) and biological (hemolysis, ROS induction, cytotoxicity and transfection) characterization was carried out followed by acute toxicity studies and therapeutic performance studies in ovariectomized rat model. Lipids with pH dependent ionization were successfully synthesized. LNPs thereof were similar to 100 nm size with stability against electrolytes, DNase I and serum and exhibited low hemolytic potential demonstrating suitability for intravenous administration. LNPs exhibited minimal cytotoxicity, non-significant ROS induction and high transfection. In vivo studies demonstrated safety and improved bone regeneration in OVX rats with HODA-LNPT showing significantly better performance. Synthesized ionizable lipids offer safe and effective alternative for preparation of LNPs for gene delivery. Targeted BMP-9 LNP show potential for systemic osteoporosis treatment.
机译:用于骨质疏松症的安全有效的全身基因递送需要用于开发脂质 - 核酸纳米粒子(LNP)的新型可电离脂质的理性设计。 LNP需要适当的静脉内施用和有效积累骨髓的有效积累,以提高转染。因此,用C18尾部和可电离的头组(Boc-His-ODA / BHODA和HIS-ODA / HODA)的脂质被合成并表征了物理化学。用骨形态发生蛋白-9基因(Bhoda-LNP,Hoda-LNP和骨归肽靶向Hoda-LNP - Hoda-LNPT)制备LNP。进行了彻底的物理化学(电解质稳定性,DNA酶I和血清稳定性)和生物学(溶血,ROS诱导,细胞毒性和转染)表征,然后进行卵巢切除大鼠模型中的急性毒性研究和治疗性能研究。成功合成了具有pH依赖性电离的脂质。其LNP与100nm尺寸相似,具有稳定性的电解质,DNA酶I和血清,并且表现出低溶血性潜力,证明静脉内给药适用性。 LNP表现出最小的细胞毒性,非显着的ROS诱导和高转染。体内研究证明了HODA-LNPT的OVX大鼠的安全性和改善了骨再生,显示出明显更好的性能。合成的可电离脂质为制备基因递送的LNP提供安全有效的替代方案。靶向BMP-9 LNP显示出系统性骨质疏松症治疗的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号